{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma&page=9",
    "query": {
      "intervention": "Plasma",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1930,
    "total_pages": 193,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T22:48:14.866Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01336023",
      "title": "Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec/liraglutide",
          "type": "DRUG"
        },
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1663,
      "start_date": "2011-05-23",
      "completion_date": "2012-11-22",
      "has_results": true,
      "last_update_posted_date": "2018-02-19",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 146,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bermuda Dunes",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336023"
    },
    {
      "nct_id": "NCT00551538",
      "title": "24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lispro mix 75/25",
          "type": "DRUG"
        },
        {
          "name": "Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2003-05",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2010-10-13",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551538"
    },
    {
      "nct_id": "NCT04959760",
      "title": "BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19 Respiratory Infection"
      ],
      "interventions": [
        {
          "name": "The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Abbott Rapid Diagnostics Jena GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 263,
      "start_date": "2021-06-03",
      "completion_date": "2022-01-20",
      "has_results": false,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Durham, North Carolina • Powdersville, South Carolina + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Powdersville",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04959760"
    },
    {
      "nct_id": "NCT04408040",
      "title": "Use of Convalescent Plasma for COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID"
      ],
      "interventions": [
        {
          "name": "Convalescent Plasma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-07-14",
      "completion_date": "2021-09-14",
      "has_results": true,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04408040"
    },
    {
      "nct_id": "NCT02504359",
      "title": "Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasma Cell Leukemia",
        "Recurrent Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib Citrate",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-07-20",
      "completion_date": "2020-09-09",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Portland, Oregon",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02504359"
    },
    {
      "nct_id": "NCT07778524",
      "title": "Alpelisib Challenge Test (ACT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Type 2 Diabetes",
        "Obesity & Overweight",
        "Healthy Adult Participants"
      ],
      "interventions": [
        {
          "name": "Alpelisib 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Hyperglycemic clamp",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-09-02",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07778524"
    },
    {
      "nct_id": "NCT04373460",
      "title": "Convalescent Plasma to Limit SARS-CoV-2 Associated Complications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasma from a volunteer donor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1225,
      "start_date": "2020-06-03",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2023-06-02",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04373460"
    },
    {
      "nct_id": "NCT07212868",
      "title": "The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Diabetic"
      ],
      "interventions": [
        {
          "name": "REMD-477 versus Placebo",
          "type": "DRUG"
        },
        {
          "name": "Exogenous glucagon versus saline infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 150,
      "start_date": "2026-02-25",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07212868"
    },
    {
      "nct_id": "NCT01404897",
      "title": "Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Disease",
        "Dyslipidemia",
        "Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Dietary Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "UCSF Benioff Children's Hospital Oakland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2011-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 1,
      "location_summary": "Berkeley, California",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404897"
    },
    {
      "nct_id": "NCT00001097",
      "title": "Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "8 Years to 22 Years"
      },
      "enrollment_count": 120,
      "start_date": "1997-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-04-26",
      "last_synced_at": "2026-10-20T22:48:14.866Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001097"
    }
  ]
}